Gilead Sciences Inc. is 10% Owner at Arcus Biosciences, Inc. (RCUS). They have made 1 open-market trade across 1 company since 2021, most recently 2021-01-31.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $220.3M since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RCUS | BUY | 2021-01-31 | 2021-02-02 | $39.00 | $220.3M | -11.1% | -17.6% | -15.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.